NewAmsterdam Pharma
Clinical trials sponsored by NewAmsterdam Pharma, explained in plain language.
A biopharmaceutical company developing therapies for cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers sought to test if experimental drug boosts antioxidant absorption. Results expected Sep 2026 (estimated) May already have reported ↗
- New combo aims to crush 'Bad' cholesterol particle that other drugs miss Results expected Nov 2026 (estimated)
-
New pill combo aims to slash cholesterol in High-Risk patients
Disease control OngoingThis Phase 3 study tests whether a daily pill combining obicetrapib and ezetimibe, or obicetrapib alone, can lower LDL (bad) cholesterol more than placebo in 300 people with type 2 diabetes or metabolic syndrome. Participants continue their standard cholesterol medications. The m…
Phase 3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
New pill could melt away heart disease plaque, major trial underway
Disease control OngoingThis study tests a daily pill (obicetrapib plus ezetimibe) to see if it can reduce fatty plaque buildup in the arteries of 300 adults with heart disease. Participants must already be on cholesterol-lowering therapy but still have high LDL cholesterol and measurable plaque. The tr…
Phase 3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC